NIHR GOSH BRC spinout Orchard Therapeutics signs strategic agreement with GSK

13 Apr 2018, 1:10 p.m.

Orchard Therapeutics logo

GSK and Orchard Therapeutics today announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard, securing the continued development of the programmes and access for patients.Orchard Therapeutics is a biotechnology company that develops transformative gene therapies for life threatening rare diseases. Orchard’s founding scientists include NIHR GOSH BRC researchers Professor Bobby Gaspar, Adrian Thrasher and Waseem Qasim. This acquisition strengthens Orchard’s position as a global leader in gene therapy for rare diseases and GSK will continue to invest in the development of its platform capabilities in cell and gene therapies, with a focus on oncology.

This agreement is evidence of GOSH BRC’s continued success in accelerating the delivery of new medicines for patient benefit and is testament to the GOSH BRC’s unique expertise in novel therapies for rare diseases.

Under the agreement, GSK will become an investor in Orchard Therapeutics, receiving a 19.9% equity stake along with a seat on the company’s board. GSK will also receive financial considerations in the form of royalties and commercial milestone payments related to the acquired portfolio. GSK and Orchard will exchange manufacturing, technical and commercial insights and learnings on the development of gene therapy medicines to ensure the success of the assets.

The acquisition of GSK’s programmes complements Orchard’s pipeline of clinical and preclinical gene therapies for primary immune deficiencies and inherited metabolic disorders.

Read more.

New director of UCL Great Ormond Street Institute of Child Health

The UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) have announced that Professor Helen Cross, an Honorary Consultant in Paediatric Neurology at GOSH, will take up the post of Director of the institute from 1 September 2022.

Can we use artificial intelligence (AI) to better diagnose fractures?

Dr Susan Shelmerdine, Consultant Paediatric Radiologist at Great Ormond Street Hospital (GOSH) discusses her research into using artificial intelligence (AI) to identify fractures in children.

People power being used to analyse eye research at GOSH

Months of work will be completed in a few days as members of the public help to examine high-resolution images of the potentially blinding eye condition, uveitis, as part of a project working across GOSH, UCL GOS ICH and Moorfields Eye Hospital.

What do young people want from Artificial Intelligence in healthcare?

Artificial intelligence in healthcare is a rapidly growing field. Children and teenagers often have insightful questions about AI, but are rarely involved in the development of new technologies. See how we're changing this...